Novavax (NVAX) Misses Q1 EPS by 13c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
May 9, 2022 4:02 PM EDTAchieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage companyReiterating full year 2022 total revenue guidance of between $4 and $5 billionContinued label expansion including primary, booster and adolescent authorizations and new shipments of Nuvaxovid into European Union, Canada, South Korea, Australia Thailand, Singapore and New Zealand Submitted request for EUA to U.S. FDA for NVX-CoV2373, with FDA Advisory Committee meeting scheduled for June 7th Announced positive Phase 1/2 results of COVID-19-Influenza Combination vaccine candidate confirming... More
